Genmab

We presented new data evaluating our investigational therapy in gynecologic oncology at the ESMO - European Society for Medical Oncology Congress.       Our latest data underscore our commitment to deliver on our vision and accelerate our late-stage pipeline of antibody medicines for patients seeking potential new options.       Read more: http://gmab.ly/aNZi50X1Qho.     #ESMO25 #GynOnc #GynecologicCancers

#ICYMI: During this edition of Antibody Hour 🕙, hear from Stephanie Lieber, Executive Director at Imerman Angels, as she shares her personal experience reinforcing how psychosocial, peer-to-peer support is so vital in cancer care.     At Genmab, we are inspired by stories like hers - reminding us that advancing science needs to go hand in hand with advancing support for patients and their care partners.     #AntibodyHour #PatientAdvocacy 

#ICYMI: We’re excited to be presenting data at this year’s ESMO - European Society for Medical Oncology Congress to connect with oncology experts and share the latest information in cancer research. Visit booth #55 to learn about our pipeline of innovative antibodies.   Learn more: http://gmab.ly/mCNg50TkooM.     #Oncology #ESMO25 

As a leader in antibody research committed to improving lives through innovative and differentiated antibody therapeutics, Genmab aims to create novel therapies that have the potential to transform the treatment of cancer and other serious diseases. To learn more, visit our new webpage at: http://gmab.ly/fr9N50X1aMt.

At Genmab, we’re driven by the profound impact that innovative antibody therapies can have on people living with cancer. Every breakthrough brings new hope, and we’re committed to advancing even more transformative treatments in the years ahead. During this edition of Antibody Hour 🕙, our colleague Emily Spencer, RN, Senior Manager, Patient Engagement Liaison, shares her vision for how cancer care could evolve over the next five years and the possibilities that inspire her every day.    Learn more about our vision and science: http://gmab.ly/wTPn50X7NqO. 

Welcome to Genmab’s October Edition of Knock-Your-Socks-Off-News, a monthly newsletter covering our current happenings across the globe. Follow along with us on our journey for more updates as we advance innovation and continue to work towards our goal of transforming the lives of patients through antibody medicines.     #culture  #news  #healthcare 

This week, we hosted our 4th annual Science Day, a day dedicated to fostering two-way dialogue with leaders from patient advocacy and professional organizations, as well as our patient advisors.  The day brought together shared perspectives and a commitment to shaping the future of science with patients at the center. At Genmab, we know progress happens when science and patient voices meet, and we’re proud to continue building those connections.  Learn more: http://gmab.ly/eiUt50TKPrz.  #ScienceDay #InspiredByPatients #PatientAdvocacy  

September is #GynecologicalCancerAwarenessMonth. Cervical cancer, a form of gynecologic cancer, was the fourth most common cancer among women globally in 2022. Learn more about cervical cancer through #CeMe, our initiative with Pfizer that aims to elevate patient voices and shed light on the realities of living with cervical cancer. #GCAM http://gmab.ly/p8UH50X38PX

#News Update: Genmab to acquire Merus, expanding our late-stage oncology pipeline and accelerating sustainable growth. Genmab has entered into an agreement to acquire Merus, a clinical-stage biotech with a breakthrough therapy in Phase 3 development for patients with advanced cancers. This proposed acquisition would diversify our promising late-stage pipeline and strengthen our foundation for sustainable growth. Fully aligned with our long-term strategy and track record in antibody innovation, it reinforces our commitment to accelerating therapies into the clinic and making a meaningful impact on patients. Learn more at: http://gmab.ly/N0Aa50X3pr8 #Oncology #Biotech

Every patient story holds immense power. This #BloodCancerAwarenessMonth, we're inspired by Arlen, who shares his journey of living with diffuse large B-cell lymphoma (#DLBCL). We believe in the transformative power of shared experience, in fostering connection, inspiring hope, and reminding us all of the strength within. Read Arlen's story: http://gmab.ly/LVCU50WTptb.